Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (13946)	7/4/2000 12:31:18 AM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Rk, Lasik that old technique that required the slashing of the cornea, You are behind, the FDA already approve Sunrise Technology for limited indications, and they will keep advancing it. It just need heating a little the cornea, no slashing like an onion!!! And, the current lasik techniques are used in MILLIONS of patients every year, and there are just few hundreds non manageable infections (requiring surgical intervention again). Rk, lets keep it there, it is almost like the people who attacks you over Yahoo!,isn't disgusting? I just give my opinions on xoma! just the facts? the little facts? the minimize pamperized till oblivion facts? that rbpi21 has not in 1800 patients showed any benefits! Unless, one trust the FDA rejected xomabaxter combination! Those subjects are more than the Lilly trial! Just pick the data and made a metaanalysis: FAILURE!

To: Robert K. who wrote (13946)	7/4/2000 1:18:40 AM
From: aknahow	Read Replies (3) \| Respond to of 17367

Robert, what do you mean nit pick, which indications will work or not work? I said, "if you think about it it will not be approved for an indication that can be cured better by something already the standard of care." This is not nit picking! It is stating the obvious and is really a statement of confidence that Neuprex and BPI peptides may well "cure" better than the existing standard of care. To think that any drug would get approved when the existing standard of care was better, (in the broadest sense cures as quickly and safely and cost less), is not logical.